Brand Intelligence Graphcompany
Company Overview
About Dexcom
Dexcom, Inc. is a San Diego, California-based diabetes management technology company — publicly traded on NASDAQ (NASDAQ: DXCM) as an S&P 500 Health Care component — developing and commercializing continuous glucose monitoring (CGM) systems for people with Type 1 diabetes, Type 2 diabetes, and pre-diabetes through approximately 9,000 employees worldwide. Dexcom's G7 CGM system (a small wearable sensor and transmitter worn on the body that measures glucose continuously every 5 minutes without fingerstick calibration) is the market-leading prescription CGM for insulin-using patients — enabling tight glucose management that prevents hypoglycemic episodes, reduces A1c levels, and improves outcomes for the 8+ million US patients using insulin. In 2024, Dexcom launched Stelo — the first FDA-cleared over-the-counter CGM in the United States, requiring no prescription and targeting the approximately 25 million US adults with Type 2 diabetes who do not use insulin, pre-diabetes patients, and health-conscious consumers seeking metabolic insights. The Stelo OTC CGM integrates with the Oura Ring (wearable health tracking) through a strategic partnership announced in November 2024, with Dexcom investing $75 million in ŌURA and the companies launching Stelo integration in the Oura app — giving users 24/7 glucose insights alongside sleep, heart rate, and activity data from the Oura Ring. Dexcom reported full year 2024 revenue of approximately $3.9 billion, with continued CGM market penetration driving growth.
Business Model & Competitive Advantage
Dexcom's CGM platform model creates competitive advantage through clinical accuracy, ecosystem integration, and insurance reimbursement coverage: the Dexcom G7's FDA-cleared MARD (mean absolute relative difference) accuracy of 8.2% sets the clinical standard that competing CGM systems must meet to gain formulary placement on insurance plans that cover CGM for insulin-using diabetics — and Dexcom's clinical data package (from 10+ years of G4/G5/G6/G7 real-world use) provides the payer evidence that newly entered competitors (from consumer health companies) cannot immediately replicate. The integration of Dexcom CGM data with insulin pumps (closed-loop artificial pancreas systems from Tandem Diabetes Care and Insulet OmniPod), insulin pen systems, and electronic health records creates a data-connected care ecosystem where Dexcom sits at the center of diabetes management workflow — generating value for patients, clinicians, and payers that individual CGM sensor sales alone do not capture.
Competitive Landscape 2025–2026
In 2025, Dexcom competes in continuous glucose monitoring and diabetes management technology against Abbott Laboratories (NYSE: ABT, FreeStyle Libre CGM — the global market share leader by installed user base in Type 2 diabetes), Medtronic (NYSE: MDT, Guardian 4 CGM and MiniMed insulin pump integration), and emerging consumer health CGMs from Levels, Supersapiens, and NutriSense for the prescription diabetes management market and the emerging OTC metabolic monitoring market. Stelo's OTC positioning opens the massive non-insulin Type 2 diabetes market (25M US patients) and the "metabolic wellness" consumer market — where health-conscious non-diabetics seek continuous glucose data to optimize diet, exercise, and sleep — a market where Apple Watch (NYSE: AAPL), Samsung Galaxy Watch, and Google (NASDAQ: GOOGL) have announced CGM feature development ambitions. The $75M Oura investment and Stelo-Oura integration represents Dexcom's strategy to embed CGM in the consumer wellness wearable ecosystem before big tech platforms commoditize glucose sensing. The 2025 strategy focuses on Stelo consumer market growth, G7 prescription market share maintenance, and CGM integration with GLP-1 medication management (Ozempic, Wegovy patients who benefit from CGM monitoring).
The Dexcom Story
Founders
Recent Activity
View all →Company Timeline
Major milestones in Dexcom's journey
Leadership Team
Meet the leaders behind Dexcom
Kevin Sayer
Kevin Sayer has served as CEO since January 2015 and Chairman of the Board since July 2018. Under his leadership, Dexcom has grown from a developing company to the global leader in CGM technology. Sayer will transition to Executive Chairman in January 2026 after a decade leading the company's transformation.
Jake Leach
Jake Leach will become President and CEO on January 1, 2026. He was given the title of President in May 2024 and currently serves as COO. Leach has worked at Dexcom for 21 years, bringing deep institutional knowledge and operational expertise to the CEO role.
Jereme Sylvain
Jereme Sylvain serves as EVP and CFO, overseeing Dexcom's financial strategy, planning, investor relations, and capital allocation. He plays a key role in supporting the company's growth trajectory and profitability initiatives.
Girish Naganathan
Girish Naganathan has served as CTO and Executive Vice President since 2022. He leads Dexcom's technology innovation, product development, and engineering efforts, driving the advancement of CGM technology and new product launches.
Michael Brown
Michael Brown has served as Chief Legal Officer and Executive Vice President since 2022. He oversees legal affairs, regulatory compliance, intellectual property, and corporate governance for Dexcom's global operations.
Sadie Stern
Sadie Stern serves as EVP and Chief Human Resources Officer, leading talent acquisition, employee engagement, diversity and inclusion initiatives, and organizational development to support Dexcom's rapid growth.
Key Differentiators
Market Leader
Dexcom is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Dexcom with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Dexcom? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Dexcom Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Dexcom vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →